Epigenetic biomarkers predict macrovascular events in individuals with type 2 diabetes.

Prediction of incident macrovascular events (iMEs) in individuals with type 2 diabetes (T2D) remains suboptimal. We aim to discover blood-based epigenetic biomarkers predicting iMEs in 752 newly diagnosed individuals with T2D, among whom 102 developed iMEs during follow-up. 461 DNA methylation sites, e.g., near ARID3A, GATA5, HDAC4, IRS2, and TMEM51, associate with iMEs. Using cross-validation, a methylation risk score (MRS) containing 87 sites predicts iMEs with an area under the curve (AUC) of 0.81 and an AUC of 0.84 for the combination of MRS and clinical risk factors, better than SCORE2-Diabetes (Systematic Coronary Risk Evaluation 2-Diabetes), UKPDS (United Kingdom Prospective Diabetes Study), Framingham, and polygenic risk scores (AUCs = 0.54-0.62). This epigenetic biomarker has a negative predictive value of 95.9% and improves the classification of iMEs with continuous net reclassification improvement (NRI) showing 90.2% improvement versus clinical factors. Atherosclerotic versus non-atherosclerotic aortas show 78 differentially methylated sites. We validate 32 sites in EPIC-Potsdam and 43 in OPTIMED cohorts, including an MRS (AUC = 0.80). Together, blood-based epigenetic biomarkers predict iMEs better than clinical risk factors, supporting its future clinical use.